The Wistar Institute Proteomics Facility

Jared Grimes

🇮🇳 India

9.3

Reviewed: March 12, 2024

• - Market Access Strategy
• - 6 weeks January - February 2024
• - Pharmaceutical Company

The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.

Blanca Simonis

🇹🇷 Turkey

8.9

Reviewed: March 3, 2023

• - Regulatory Submission
• - 6 weeks February 2023
• - Biotech Startup

Our regulatory submission was handled with great care and expertise. The process was seamless, and their knowledge of the regulatory landscape was impressive. The team's support was invaluable, and I would not hesitate to use their services again.

Cristina Weissnat

🇷🇺 Russia

6.2

Reviewed: March 15, 2024

• - Clinical Protocol Design
• - 10 weeks January - March 2024
• - Pharmaceutical Company

The protocol design process required multiple revisions due to inconsistencies in the deliverables. Although the team was responsive to feedback, the back-and-forth extended the timeline beyond what was originally agreed upon.

Kenny Gleichner

🇨🇳 China

9.2

Reviewed: January 10, 2024

• - Data Visualization
• - 3 weeks December 2023
• - Pharmaceutical Company

The data visualization services were highly effective, making complex data easy to interpret and communicate. The visualizations were impactful and played a crucial role in our stakeholder presentations.

Teri Gorczany

🇰🇷 South Korea

9.1

Reviewed: August 11, 2023

• - Clinical Data Management
• - 6 weeks June - July 2023
• - CRO

The data management services were delivered on time and with great accuracy. Collaboration with the team was smooth, and they were always available to address any concerns or questions we had. We were very satisfied with the outcome.

Misty Fahey

🇫🇷 France

9

Reviewed: June 18, 2023

• - Clinical Protocol Design
• - 6 weeks April - May 2023
• - Pharmaceutical Company

The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.

Ernest Witting

🇲🇽 Mexico

5.8

Reviewed: April 5, 2024

• - Biostatistical Design
• - 6 weeks February - March 2024
• - Research Institution

The biostatistical analysis provided was not as thorough as we had hoped. Some key insights were missed, and we had to engage another provider to get the level of detail we needed. The team seemed overworked and under-resourced.